AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16 (cancelled).

17 (new). A method of treating a disease or condition in an animal, the method comprising administering to the animal a pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin, wherein said GnRH agonist is other than deslorelin.

18 (new). A method according to claim 17, wherein the formulation comprises about 5-10% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-1.5% (w/w) lecithin and 89-94% (w/w) stearin.

19 (new). A method according to claim 17, wherein the lecithin and stearin are in non-crystalline form.

20. A method of treating a disease or condition in an animal for which suppression of sex hormone levels is beneficial, the method comprising administering to the animal a pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-3.5%

TRIGG et al Appl. No. 10/808;504 August 4, 2004

(w/w) lecithin and the balance stearin, wherein said GnRH agonist is other than deslorelin to ameliorate said disease or condition.

21 (new). A method according to claim 20, wherein the formulation comprises about 5-10% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-1.5% (w/w) lecithin and 89-94% (w/w) stearin.

22 (new). A method according to claim 20, wherein the disease or condition is selected from the group consisting of prostate cancer, ovarian and breast cancer, endometriosis, myoma, pre-menstrual tension, uterine fibroids, hirsutism, cyclic auditory dysfunction, porphyria and precocious puberty.

23 (new). A method according to claim 20, wherein the lecithin and stearin are in a non-crystalline form.

24 (new). A method of preventing reproductive function from functioning in an animal, the method comprising administering to the animal a pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin, wherein said GnRH agonist is other than deslorelin.

25 (new). A method according to claim 24, wherein the formulation comprises about 5-10% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-1.5% (w/w) lecithin and 89-94% (w/w) stearin.

26 (new). A method according to claim 24, wherein the lecithin and stearin are in non-crystalline form.

27 (new). A method of treating benign prostatic hyperplasia in an animal, the method comprising administering to the animal a pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin, wherein said GnRH agonist is other than deslorelin whereby treating the benign prostatic hyperplasia.

28 (new). A method according to claim 27, wherein the formulation comprises about 5-10% (w/w) of at least one GnRH agonist (on an active basis), about 0.5-1.5% (w/w) lecithin and 89-94% (w/w) stearin.

29 (new). A method according to claim 27, wherein the animal being treated is a dog.

30 (new). A method according to claim 27, wherein the lecithin and stearin are in non-crystalline form.